A shortage of BCG is foreseen till the end of 2013.
Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available? In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice is radical cystectomy. Device-assisted therapies, although showing promising results, should be considered only for selected patients. In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG is available. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferably preceded by early instillation, according to the EAU guidelines.

Written by:
Serretta V, Colombo R. Are you the author?
Sezione di Urologia, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo - Italy.
Reference: Urologia. 2013 Mar 22;0(0):0.
doi: 10.5301/RU.2013.10860
PubMed Abstract
PMID: 23559137
Article in Italian.
UroToday.com Bladder Cancer Section
